Payment overview · 2025
General Payments
$2,128.69
98 reported records · 24 companies
Healthcare provider profile · identity verified
Dwayne Oneal Williams, MD
Allopathic & Osteopathic Physicians|Family Medicine · SUGAR LAND, TX · NPI 1689740003
Verified facts
What the public records show
CMS Open Payments records show Dwayne Oneal Williams, MD received $2,128.69 in general payments during 2025 across 98 reported records.
Novo Nordisk Inc accounted for 17.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Zenpep by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 297 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 291 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $367.87 | 17.3% | 19 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $238.32 | 11.2% | 10 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $152.29 | 7.2% | 8 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $137.02 | 6.4% | 6 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $122.65 | 5.8% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $110.04 | 5.2% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $109.15 | 5.1% | 4 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $102.34 | 4.8% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $97.64 | 4.6% | 5 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $95.29 | 4.5% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $82.48 | 3.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $81.48 | 3.8% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $76.06 | 3.6% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $75.24 | 3.5% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $68.71 | 3.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.55 | 1.8% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $32.92 | 1.6% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $24.62 | 1.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.41 | 1.1% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $21.65 | 1.0% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $19.84 | 0.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.94 | 0.8% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $17.81 | 0.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.37 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,128.69 | 98 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $191.91 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $188.31 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $188.31 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $175.96 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $175.72 | 9 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $137.02 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $134.88 | 6 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $122.65 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $110.04 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $110.04 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $109.15 | 4 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $102.34 | 5 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $95.29 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $82.48 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $81.48 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $75.24 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $68.71 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $54.30 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $43.34 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $43.34 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $41.70 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $38.55 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $34.36 | 2 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $32.92 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $24.62 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.41 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| Linzess Normalized: linzess |
Drug | IRONWOOD PHARMACEUTICALS, INC | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $14.47 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 99 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 69 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Linzess linzess |
2025 | Linzess | 2024 | 83 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 297 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 291 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 173 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 29 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
83 | 26 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
65 | 17 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 21 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | 12 |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
83 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
297 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
291 | 54 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
173 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
107 | 34 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 722 | 238 |
| Montelukast Sodium | Montelukast Sodium | 428 | 150 |
| Amlodipine Besylate | Amlodipine Besylate | 416 | 144 |
| Gabapentin | Gabapentin | 317 | 110 |
| Mounjaro | Tirzepatide | 297 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 293 | 94 |
| Ozempic | Semaglutide | 291 | 54 |
| Losartan Potassium | Losartan Potassium | 273 | 83 |
| Zolpidem Tartrate | Zolpidem Tartrate | 271 | 49 |
| Tizanidine Hcl | Tizanidine Hcl | 247 | 78 |
| Metformin Hcl | Metformin Hcl | 203 | 68 |
| Lisinopril | Lisinopril | 202 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 194 | 56 |
| Alprazolam | Alprazolam | 190 | 33 |
| Azithromycin | Azithromycin | 188 | 129 |
| Pantoprazole Sodium | Pantoprazole Sodium | 175 | 63 |
| Rybelsus | Semaglutide | 173 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 166 | 52 |
| Alendronate Sodium | Alendronate Sodium | 164 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 156 | 61 |
| Carvedilol | Carvedilol | 155 | 53 |
| Omeprazole | Omeprazole | 154 | 54 |
| Furosemide | Furosemide | 144 | 63 |
| Meloxicam | Meloxicam | 139 | 57 |
| Methylprednisolone | Methylprednisolone | 130 | 73 |
| Trazodone Hcl | Trazodone Hcl | 130 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 128 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 124 | 45 |
| Metformin Hcl Er | Metformin Hcl | 122 | 40 |
| Sertraline Hcl | Sertraline Hcl | 122 | 36 |
| Simvastatin | Simvastatin | 117 | 35 |
| Buspirone Hcl | Buspirone Hcl | 114 | 38 |
| Pregabalin | Pregabalin | 114 | 25 |
| Nifedipine Er | Nifedipine | 113 | 37 |
| Tramadol Hcl | Tramadol Hcl | 113 | 33 |
| Donepezil Hcl | Donepezil Hcl | 110 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 108 | 49 |
| Eliquis | Apixaban | 107 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 104 | 31 |
| Celecoxib | Celecoxib | 103 | 33 |
| Jardiance | Empagliflozin | 99 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 88 | 32 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 85 | 71 |
| Januvia | Sitagliptin Phosphate | 84 | 16 |
| Potassium Chloride | Potassium Chloride | 84 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 27 |
| Linzess | Linaclotide | 83 | 26 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 82 | 28 |
| Allopurinol | Allopurinol | 81 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 78 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 76 | 42 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 74 | 21 |
| Bumetanide | Bumetanide | 70 | 22 |
| Xarelto | Rivaroxaban | 70 | 17 |
| Kerendia | Finerenone | 69 | suppressed |
| Clonazepam | Clonazepam | 67 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 66 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 65 | 48 |
| Synthroid | Levothyroxine Sodium | 65 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 65 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 19 |
| Eszopiclone | Eszopiclone | 63 | 18 |
| Glimepiride | Glimepiride | 62 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 62 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 60 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 60 | 20 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 59 | 13 |
| Ibuprofen | Ibuprofen | 58 | 22 |
| Ezetimibe | Ezetimibe | 56 | 16 |
| Meclizine Hcl | Meclizine Hcl | 55 | 21 |
| Temazepam | Temazepam | 55 | suppressed |
| Lidocaine | Lidocaine | 54 | 23 |
| Atenolol | Atenolol | 53 | 15 |
| Tradjenta | Linagliptin | 52 | suppressed |
| Glipizide Er | Glipizide | 51 | 17 |
| Valsartan | Valsartan | 51 | 13 |
| Famotidine | Famotidine | 48 | 14 |
| Farxiga | Dapagliflozin Propanediol | 47 | 14 |
| Memantine Hcl | Memantine Hcl | 45 | 15 |
| Mupirocin | Mupirocin | 45 | 16 |
| Naproxen | Naproxen | 45 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 13 |
| Warfarin Sodium | Warfarin Sodium | 44 | suppressed |
| Spironolactone | Spironolactone | 43 | 15 |
| Glipizide | Glipizide | 42 | 13 |
| Hydrocortisone | Hydrocortisone | 42 | 14 |
| Ondansetron Odt | Ondansetron | 40 | 15 |
| Ramelteon | Ramelteon | 39 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 17 |
| Diazepam | Diazepam | 36 | 12 |
| Valacyclovir | Valacyclovir Hcl | 36 | 12 |
| Baclofen | Baclofen | 35 | 12 |
| Prednisone | Prednisone | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Levetiracetam | Levetiracetam | 34 | 12 |
| Amoxicillin | Amoxicillin | 33 | 18 |
| Nabumetone | Nabumetone | 33 | suppressed |
| Telmisartan | Telmisartan | 33 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 32 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | suppressed |
| Triazolam | Triazolam | 31 | suppressed |
| Sucralfate | Sucralfate | 30 | 17 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Lorazepam | Lorazepam | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | 12 |
| Gemtesa | Vibegron | 28 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 18 |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 26 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 18 |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Finasteride | Finasteride | 20 | 12 |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 19 | suppressed |
| Indapamide | Indapamide | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Clotrimazole | Clotrimazole | 18 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Silodosin | Silodosin | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | 13 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | 11 |
| Fluconazole | Fluconazole | 16 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Tadalafil | Tadalafil | 14 | suppressed |
| Toprol Xl | Metoprolol Succinate | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 13 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 13 | suppressed |
| Etodolac | Etodolac | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,128.69 · 98 records | Novo Nordisk Inc | ACCRUFER, AIRSUPRA, AREXVY, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, Dyanavel XR, FREESTYLE LIBRE 3, GEMTESA, IBSRELA, JARDIANCE, Kerendia, Korlym, LOREEV XR, Linzess, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, RELISTOR, REPATHA, RUKOBIA, Rybelsus, SHINGRIX, Saxenda, TRELEGY ELLIPTA, TRULANCE, UBRELVY, Veozah, Wegovy, ZAVZPRET, ZENPEP, ZEPBOUND | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error